Toci patients who developed aGVHD by day 100 (n = 35)
| Organ stage . | Skin . | Upper GI . | Lower GI . | Liver . |
|---|---|---|---|---|
| 0 | 21 (60%) | 6 (17%) | 28 (80%)∗ | 32 (91%) |
| 1 | 5 (14%) | 29 (83%) | 3 (9%) | 0 |
| 2 | 7 (20%) | - | 1 (3%) | 1 (3%) |
| 3 | 2 (6%) | - | 1 (3%) | 1 (3%) |
| 4 | 0 | - | 2 (6%) | 1 (3%) |
| Organ stage . | Skin . | Upper GI . | Lower GI . | Liver . |
|---|---|---|---|---|
| 0 | 21 (60%) | 6 (17%) | 28 (80%)∗ | 32 (91%) |
| 1 | 5 (14%) | 29 (83%) | 3 (9%) | 0 |
| 2 | 7 (20%) | - | 1 (3%) | 1 (3%) |
| 3 | 2 (6%) | - | 1 (3%) | 1 (3%) |
| 4 | 0 | - | 2 (6%) | 1 (3%) |
A total of 7 patients had stage 0+ lower GI GVHD (<500 mL/day).